Neuropsychiatric symptoms (NPS) carry an increased risk of progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). There is a need to understand how to integrate NPS into the paradigm outlined in the 2018 NIA-AA Research Framework.
Objective:
To evaluate a prediction model of MCI-AD progression using a collection of variables, including NPS, cognitive testing, apolipoprotein E4 status (APOE4), imaging and laboratory AD biomarkers.
Methods:
Of 300 elderly subjects, 219 had stable MCI and 81 MCI-AD progression over a 5-year follow-up. NPS were measured using the Neuropsychiatric Inventory (NPI). A multivariate Cox Proportional Hazards Regression Analysis assessed the effects of APOE4, baseline NPI, baseline CSF amyloid-β, phosphorylated and total tau, baseline AD-signature MRI biomarker, baseline memory and executive function on MCI-AD progression.
Results:
27% progressed to dementia (median follow-up = 43 months). NPS were found in stable MCI (62.6%) and MCI-AD converters (70.3%). The Cox model exhibited a good fit (p < 0.001), and NPS (HR = 1.033, p = 0.027), phosphorylated tau (HR = 1.011, p = 0.025), total tau (HR = 1.005, p = 0.024), AD-signature MRI biomarker (HR = 0.111, p = 0.002), executive function (HR = 0.727, p = 0.045), and memory performance (HR = 0.387, p < 0.001) were significantly associated with dementia.
Conclusions:
NPS may inform dementia risk assessment in conjunction with cognitive testing and imaging and laboratory AD biomarkers. NPS is independently associated with the risk of MCI-dementia progression, over and beyond the contributions of CSF biomarkers.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology34, 939–944.
DuboisB, HampelH, FeldmanHH, ScheltensP, AisenP, AndrieuS, BakardjianH, BenaliH, BertramL, BlennowK, BroichK, CavedoE, CrutchS, DartiguesJF, DuyckaertsC, EpelbaumS, FrisoniGB, GauthierS, GenthonR, GouwAA, HabertMO, HoltzmanDM, KivipeltoM, ListaS, MolinuevoJL, O’BryantSE, RabinoviciGD, RoweC, SallowayS, SchneiderLS, SperlingR, TeichmannM, CarrilloMC, CummingsJ, JackCRJr.Proceedings of the Meeting of the International Working G, the American Alzheimer’s Association on “The Preclinical State of AD, July, Washington Dc USA (2016) Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement12, 292–323.
RosenbergPB, MielkeMM, ApplebyBS, OhES, GedaYE, LyketsosCG (2013) The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry21, 685–695.
7.
GallagherD, FischerCE, IaboniA (2017) Neuropsychiatric symptoms in mild cognitive impairment. Can J Psychiatry62, 161–169.
8.
ZhaoQF, TanL, WangHF, JiangT, TanMS, TanL, XuW, LiJQ, WangJ, LaiTJ, YuJT (2016) The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord190, 264–271.
9.
StellaF, RadanovicM, BalthazarMLF, CanineuPR, de Souza LC, ForlenzaOV (2014) Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry27, 230–235.
10.
RobertoN, PortellaMJ, MarquieM, AlegretM, HernandezI, MauleonA, Rosende-RocaM, AbdelnourC, de Antonio EE, GilS, TartariJP, VargasL, EspinosaA, OrtegaG, Perez-CordonA, SanabriaA, OrellanaA, de Rojas I, Moreno-GrauS, MontrrealL, Alarcon-MartinE, RuizA, TarragaL, BoadaM, ValeroS (2021) Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep11, 6448.
11.
PalmerK, BergerAK, MonasteroR, WinbladB, BackmanL, FratiglioniL (2007) Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology68, 1596–1602.
12.
RobertPH, BerrC, VolteauM, Bertogliati-FileauC, BenoitM, GuerinO, SarazinM, LegrainS, DuboisB, PreALSG (2008) Importance of lack of interest in patients with mild cognitive impairment. Am J Geriatr Psychiatry16, 770–776.
13.
MartinE, VelayudhanL (2020) Neuropsychiatric symptoms in mild cognitive impairment: A literature review. Dement Geriatr Cogn Disord49, 146–155.
14.
AcostaI, BorgesG, Aguirre-HernandezR, SosaAL, PrinceM (2018) Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: A 10/66 Dementia Research Group study. Alzheimers Dement14, 271–279.
15.
EhrenbergAJ, SuemotoCK, Franca Resende EP, PetersenC, LeiteREP, RodriguezRD, Ferretti-RebustiniREL, YouM, OhJ, NitriniR, PasqualucciCA, Jacob-FilhoW, KramerJH, GatchelJR, GrinbergLT (2018) Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis66, 115–126.
16.
BensamounD, GuignardR, FurstAJ, DerreumauxA, ManeraV, DarcourtJ, BenoitM, RobertPH, DavidR (2016) Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis49, 387–398.
17.
DonovanNJ, LocascioJJ, MarshallGA, GatchelJ, HanseeuwBJ, RentzDM, JohnsonKA, SperlingRA,
Harvard Aging Brain Study
(2018) Longitudinal association of amyloid beta and anxious-depressive symptoms in cognitively normal older adults. Am J Psychiatry175, 530–537.
18.
MahL, BinnsMA, SteffensDC, Alzheimer’s Disease Neuroimaging Initiative
(2015) Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry23, 466–476.
19.
YasunoF, MinamiH, HattoriH,
Alzheimer’s Disease Neuroimaging Initiative
(2021) Relationship between neuropsychiatric symptoms and Alzheimer’s disease pathology: An positron emission tomography study. }, Int J Geriatr Psychiatry36, 598–605.
20.
TommasiNS, GonzalezC, BriggsD, ProperziMJ, GatchelJR, MarshallGA, Alzheimer’s Disease Neuroimaging Initiative
(2021) Affective symptoms and regional cerebral tau burden in early-stage Alzheimer’s disease. Int J Geriatr Psychiatry36, 1050–1058.
21.
NgKP, ChiewH, Rosa-NetoP, KandiahN, IsmailZ, GauthierS (2021) Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Transl Neurodegener10, 11.
22.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients, Neurology48, S10–16.
23.
CranePK, CarleA, GibbonsLE, InselP, MackinRS, GrossA, JonesRN, MukherjeeS, CurtisSM, HarveyD, WeinerM, MungasD, Alzheimer’s Disease Neuroimaging Initiative
(2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav6, 502–516.
24.
GibbonsLE, CarleAC, MackinRS, HarveyD, MukherjeeS, InselP, CurtisSM, MungasD, CranePK,
Alzheimer’s Disease Neuroimaging Initiative
(2012) A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav6, 517–527.
DickersonBC, BakkourA, SalatDH, FeczkoE, PachecoJ, GreveDN, GrodsteinF, WrightCI, BlackerD, RosasHD, SperlingRA, AtriA, GrowdonJH, HymanBT, MorrisJC, FischlB, BucknerRL (2009) The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex19, 497–510.
28.
BakkourA, MorrisJC, WolkDA, DickersonBC (2013) The effects of aging and Alzheimer’s disease on cerebral cortical anatomy: Specificity and differential relationships with cognition. Neuroimage76, 332–344.
29.
BakkourA, MorrisJC, DickersonBC (2009) The cortical signature of prodromal AD: Regional thinning predicts mild AD dementia. Neurology72, 1048–1055.
30.
SantabarbaraJ, VillagrasaB, Lopez-AntonR, OlayaB, Bueno-NotivolJ, de la CamaraC, Gracia-GarciaP, LoboE, LoboA (2019) Clinically relevant anxiety and risk of Alzheimer’s disease in an elderly community sample: 4.5 years of follow-up. J Affect Disord250, 16–20.
31.
BurkeSL, CadetT, AlcideA, O’DriscollJ, MaramaldiP (2018) Psychosocial risk factors and Alzheimer’s disease: The associative effect of depression, sleep disturbance, and anxiety. Aging Ment Health22, 1577–1584.
32.
GedaYE, SchneiderLS, GitlinLN, MillerDS, SmithGS, BellJ, EvansJ, LeeM, PorsteinssonA, LanctôtKL, RosenbergPB, SultzerDL, FrancisPT, BrodatyH, PadalaPP, OnyikeCU, OrtizLA, Ancoli-IsraelS, BliwiseDL, MartinJL, VitielloMV, YaffeK, ZeePC, HerrmannN, SweetRA, BallardC, KhinNA, AlfaroC, MurrayPS, SchultzS, LyketsosCG (2013) Neuropsychiatric symptoms in Alzheimer’s disease: Past progress and anticipation of the future. Alzheimers Dement9, 602–608.
33.
ChenY, DangM, ZhangZ (2021) Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: A systematic review of symptom-general and -specific lesion patterns. Mol Neurodegener16, 38.
34.
JichaGA, CarrSA (2010) Conceptual evolution in Alzheimer’s disease: Implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis19, 253–272.
35.
LanariA, AmentaF, SilvestrelliG, TomassoniD, ParnettiL (2006) Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer’s disease. Mech Ageing Dev127, 158–165.
36.
RamakersIH, VerheyFR, ScheltensP, HampelH, SoininenH, AaltenP, RikkertMO, VerbeekMM, SpiruL, BlennowK, TrojanowskiJQ, ShawLM, VisserPJ, Alzheimer’s Disease Neuroimaging Initiative and DESCRIPA Investigators
(2013) Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med43, 911–920.
37.
TissotC, TherriaultJ, PascoalTA, ChamounM, LussierFZ, SavardM, MathotaarachchiSS,
A LB, ThomasEM, ParsonsM, NasreddineZ, Rosa-NetoP, GauthierS (2021) Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer’s disease, Alzheimers Dement (N Y)7, e12154.
ApostolovaLG, CummingsJL (2008) Neuropsychiatric manifestations in mild cognitive impairment: A systematic review of the literature. Dement Geriatr Cogn Disord25, 115–126.
45.
ForsellY, PalmerK, FratiglioniL (2003) Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand Suppl179, 25–28.
46.
LyketsosCG, LopezO, JonesB, FitzpatrickAL, BreitnerJ, DeKoskyS (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA288, 1475–1483.
47.
KlunkWE (2011) Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia, Neurobiol Aging32 Suppl 1, S20–36.
48.
JeffersonAL, BeiserAS, SeshadriS, WolfPA, AuR (2015) APOE and mild cognitive impairment: The Framingham Heart Study. Age Ageing44, 307–311.
49.
BoylePA, BuchmanAS, WilsonRS, KellyJF, BennettDA (2010) The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology34, 43–49.
50.
SuzukiK, HirakawaA, IharaR, IwataA, IshiiK, IkeuchiT, SunCK, DonohueM, IwatsuboT, Alzheimer’s Disease Neuroimaging Initiative, Japanese Alzheimer’s Disease Neuroimaging Initiative (2020) Effect of apolipoprotein E epsilon4 allele on the progression of cognitive decline in the early stage of Alzheimer’s disease, Alzheimers Dement (N Y)6, e12007.
51.
FeldmanH, GauthierS, HeckerJ, VellasB, SubbiahP, WhalenE, Donepezil MSAD Study Investigators Group (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology57, 613–620.
